Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Baby supplement study: will extra nutrients boost growth?

NCT ID NCT07630584

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times

Summary

This study looks at whether giving healthy infants dietary supplements from birth to 2.5 months old affects their growth, digestion, and health markers. About 327 babies will be randomly assigned to receive either a supplement or a placebo. The goal is to learn more about infant nutrition, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 327 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 28 days

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent has been obtained from at least one parent (or legally acceptable representative \[LAR\]) 2. Parent(s) / LAR(s) must be able to provide evidence of parental authority and identity 3. Parent(s) / LAR(s) must understand the informed consent form and other study documents 4. Parent(s) / LAR(s) are willing and able to comply with scheduled visits and the requirements of the study protocol 5. Parent(s) / LAR(s) can be contacted directly by telephone throughout the study 6. Parent(s) / LAR(s) must be able to temporarily store stool samples in a household freezer 7. Infants may be exclusively breastfed, exclusively formula-fed, or mixed fed with both breast milk and infant formula in any proportion. Parent(s) / LAR(s) must intend to maintain the infant's current mode of feeding until the end of the study period: 1. For exclusively breastfed infants: parents must intend to continue exclusive breastfeeding. As defined by the World Health Organization, exclusive breastfeeding means that the infant receives only breast milk. No other liquids or solids are given (not even water) with the exception of oral rehydration solution, or drops/syrups of vitamins, minerals, or medicines. 2. For formula-fed infants (either exclusively or mixed-fed): parent(s) / LAR(s) must intend to maintain the infant's current mode of feeding, plus: * Parents / LAR(s) must have previously and independently decided to use formula * Infant must be consuming and tolerating a standard cow's milk infant formula not containing probiotics at the time of enrollment 8. Infant must be healthy based on medical history and physical examination 9. Infant full-term gestational birth (born 37 weeks, 0 days through 41 weeks, 6 days of gestation) 10. Infant singleton birth 11. Infant postnatal age ≥ 14 and ≤ 28 days (date of birth = day 0) 12. Infant birth weight is appropriate for gestational age (≥ 2500 and ≤ 4500 grams) Exclusion Criteria: 1. Infants with conditions requiring specific infant feeding regimens other than those specified in the protocol 2. Infants who have a medical condition or medical history that could increase the risk associated with study participation or interfere with the interpretation of study results, including: 1. Evidence of major congenital malformations (e.g., cleft palate, extremity malformation) 2. Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis) 3. Previous or ongoing antibiotic usage by the infant, except when given for prophylactic reasons (e.g., erythromycin ophthalmic ointment) 4. Immunocompromised infants and those who have a central venous catheter 5. History of admission to the Neonatal Intensive Care Unit, except for admission for jaundice phototherapy 6. Known or suspected allergy to milk (including lactose) or soy 7. Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgement of the investigator, would make the infant inappropriate for entry into the study 3. Infants who are currently receiving or who have received any probiotic supplements or infant formula containing probiotics prior to enrollment 4. Infants who are currently receiving or who have received any of the following medication(s) or supplement(s) which are known or suspected to affect fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes), stool characteristics (e.g., glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose), growth (e.g. insulin or growth hormone), microbiome-related endpoints (e.g., prebiotic supplements), or gastric acid secretion 5. Infants whose parent(s) / LAR(s) have not reached the legal age of majority (18 years old) 6. Infants who are currently or who previously participated in another interventional clinical study 7. Parent(s) / LAR(s) with family or hierarchical relationships with the research team members

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy infants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Health Index Multispecialty and Lying-In Clinic

    RECRUITING

    Cavite City, Manila, Philippines

  • University of the East Ramon Magsaysay Memorial Medical Center, Inc.

    RECRUITING

    Quezon City, Manila, Philippines

More trials for these conditions

Other studies related to the condition(s) this trial covers.